Agilent Technologies Inc. (NYSE: A) announces the 10th anniversary of the Agilent BioTek Cytation 3 cell imaging multimode reader and the Agilent BioTek line of imaging and microscopy instruments. Since its launch, thousands of researchers globally have used the Agilent BioTek Cytation line of instruments to advance the frontiers of scientific knowledge.
Light microscopy has served as an essential instrument of discovery across the life sciences for centuries. Ten years ago, Agilent BioTek built upon this foundation by introducing the BioTek Cytation 3 cell imaging multimode reader and the concept of augmented microscopy—creating an automated solution to take researchers from image capture to publication-ready data.
When the Cytation 3 cell imaging multimode reader was launched, automated imaging was democratized due to its feature set and price point. Before this product, researchers had to choose between a traditional microscope or an expensive high-content screening imaging system. Cytation 3 opened the doors of automated imaging to every lab. As a result, this revolutionary product has driven many scientific discoveries, as evidenced by the thousands of peer-reviewed publications citing BioTek Cytation products.
Agilent BioTek has continued to evolve this critical product line to broaden its capabilities. The most recent Agilent BioTek Cytation C10 confocal imaging reader combines traditional multimode microplate detection with widefield and spinning disk confocal microscopy within a single device. Confocal microscopy enables a level of detail in samples that is not possible with widefield optics, and this approach accelerates research by allowing labs to work on live, 3D-cellular models. These models are at the forefront of current disease and drug discovery research.
“The Cytation 3 enables customers to collect, process, and analyze thousands of data points with the click of a button,” said Xavier Amouretti, vice president and general manager of the BioTek product line at Agilent. “The images acquired and analyzed in our software provide insight into a range of high-growth markets related to cancer research, infectious disease, and drug discovery.”